EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Delta

Ensembl ID : ENSOMEG00000016651
Gene Symbol: GABRD
1 Cross references
193 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma1

Ensembl ID : ENSOMEG00000006413
Gene Symbol: GABRG1
3 Cross references
187 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma2

Ensembl ID : ENSOMEG00000004910
Gene Symbol: GABRG2
3 Cross references
206 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSOMEG00000003739
Gene Symbol: GABRG3
4 Cross references
215 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSOMEG00000004966
Gene Symbol: GABRG3
4 Cross references
214 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSOMEG00000007984
Gene Symbol: GABBR1
3 Cross references
190 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1-Like

Ensembl ID : ENSOMEG00000019713
Gene Symbol: LOC112136620
2 Cross references
197 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 2

Ensembl ID : ENSOMEG00000014632
Gene Symbol: GABBR2
3 Cross references
208 Possible Orthologues:

Glucagon Like Peptide 2 Receptor

Ensembl ID : ENSOMEG00000002336
Gene Symbol: GLP2R
2 Cross references
205 Possible Orthologues:

Glucocorticoid Receptor-Like

Ensembl ID : ENSOMEG00000007143
Gene Symbol: LOC112153800
3 Cross references
205 Possible Orthologues:

Glucokinase

Ensembl ID : ENSOMEG00000016412
Gene Symbol: GCK
3 Cross references
211 Possible Orthologues:

Glucosylceramidase Beta 1

Ensembl ID : ENSOMEG00000008476
Gene Symbol: GBA1
3 Cross references
251 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).